Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7550484B2 · kind B2 · utility
16Cited by
8References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 22, 2004 |
| Grant date | Jun 23, 2009 |
| Priority date | — |
| Expiry date | Nov 29, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds that interact with the CXCR4 receptor are described. These compounds are useful in treating, for Example, HIV infection and inflammatory conditions such as rheumatoid arthritis, as well as asthma or cancer, and are useful in methods to elevate progenitor and stem cell counts as well as methods to elevate white blood cell counts.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.